Abstract
Background: The frequency and clinical features of drug-related taste and/or smell impairments are currently unclear. Objective: The aim of this study was to identify major drug classes associated with taste and smell alterations reported to the Italian spontaneous adverse drug reaction (ADR) reporting database. Methods: The association between drug and altered taste or smell was investigated by case/non-case methodology. The reporting odds ratio (ROR) was used as a measure of disproportionality. Cases were defined as patients with at least one ADR related to taste or smell impairments. The non-cases included all patients without any ADRs related to taste or smell alterations. Results: According to the selection criteria, 52 166 reports were included in the analysis. Overall, 182 cases of drug-related taste and/or smell dysfunctions were identified. Statistically significant unadjusted RORs were reported for macrolides (n = 31; 7.1; 95% CI 4.8, 10.5), terbinafine (the only drug reported within the group of antimycotics belonging to the Anatomical Therapeutic Chemical class D01AE) [n = 17; 76.4; 95% CI 44.0, 132.6], fluoroquinolones (n = 15; 1.7; 95% CI 1.0, 2.8) and protein kinase inhibitors (n = 10; 4.0; 95% CI 2.1, 7.7). When RORs were adjusted for sex and age category, the disproportion remained statistically significant for all of the previously mentioned drug classes. © 2011 Adis Data Information BV. All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 849-859 |
Number of pages | 11 |
Journal | Drug Safety |
Volume | 34 |
Issue number | 10 |
DOIs | |
Publication status | Published - 1 Jan 2011 |
Keywords
- Antifungals
- Dysgeusia
- Dysosmia
- Fluoroquinolones
- Macrolides
- Olfaction-disorders
- Protein-kinase-inhibitors
- Taste-disorders
- Terbinafine
- amoxicillin plus clavulanic acid
- antifungal agent
- azithromycin
- beclometasone
- ciprofloxacin
- clarithromycin
- dipeptidyl carboxypeptidase inhibitor
- erlotinib
- hydroxymethylglutaryl coenzyme A reductase inhibitor
- imatinib
- levofloxacin
- lomefloxacin
- macrolide
- moxifloxacin
- norfloxacin
- protein kinase inhibitor
- proton pump inhibitor
- quinoline derived antiinfective agent
- ramipril
- roxithromycin
- simvastatin
- sunitinib
- telithromycin
- terbinafine
- adult
- aged
- ageusia
- anosmia
- article
- bronchitis
- chronic bronchitis
- clinical feature
- data base
- drug dose titration
- drug withdrawal
- dysgeusia
- female
- follow up
- gastrointestinal stromal tumor
- human
- kidney cancer
- major clinical study
- male
- methodology
- priority journal
- smelling disorder
- taste disorder
- unspecified side effect